ADVERTISEMENT

Suven Pharma Q3 Results Review - In Cross Roads Of Acquisition: Dolat Capital

Advent international (Global PE) has made an offer to acquire 50.1% stake in Suven Pharma.

A scientist at R&D facility of Suven Pharmaceuticals Ltd. (Source: Company website)
A scientist at R&D facility of Suven Pharmaceuticals Ltd. (Source: Company website)
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy. 
To continue reading this story
You must be an existing Premium User
OUR NEWSLETTERS
By signing up you agree to the Terms & Conditions of NDTV Profit